A carregar...
A head‐to‐head comparison of ixekizumab vs. guselkumab in patients with moderate‐to‐severe plaque psoriasis: 24‐week efficacy and safety results from a randomized, double‐blinded trial
BACKGROUND: Significantly more patients with moderate‐to‐severe plaque psoriasis treated with the interleukin (IL)‐17A inhibitor ixekizumab vs. the IL‐23p19 inhibitor guselkumab in the IXORA‐R head‐to‐head trial achieved 100% improvement in Psoriasis Area and Severity Index (PASI 100) at week 12. OB...
Na minha lista:
| Publicado no: | Br J Dermatol |
|---|---|
| Main Authors: | , , , , , , , , , , , , , , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
John Wiley and Sons Inc.
2020
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8246960/ https://ncbi.nlm.nih.gov/pubmed/32880909 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/bjd.19509 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|